AB Sciex announces agreement to market MS solutions

January 27, 2012

LCGC Europe eNews

LCGC Europe eNews-01-27-2012, Volume 0, Issue 0

AB Sciex and Indigo BioSystems have announced an agreement to jointly market mass spectrometry solutions that streamline data acquisition and automate data review to ensure high quality results in clinical research, forensic toxicology and pre-clinical and clinical trials of new drugs.

AB Sciex and Indigo BioSystems have announced an agreement to jointly market mass spectrometry solutions that streamline data acquisition and automate data review to ensure high quality results in clinical research, forensic toxicology and pre-clinical and clinical trials of new drugs.

This joint venture is expected to accelerate the use of new-generation mass spectrometry technologies for those who are accustomed to using easy-to-use lab analysers.

Joe Anacleto, vice president of Applied Markets and Clinical Research, AB Sciex, said, “Automation is an important step to accelerate the adoption of new-generation mass spectrometry for clinical research, forensics and clinical trials. Our relationship with Indigo BioSystems allows us to bring LC–MS–MS solutions to researchers who may not ordinarily consider mass spectrometry but can now have the assurance of a simplified workflow while getting all the attractive benefits of LC–MS–MS technology.”

Raul Zavaleta, Indigo CEO, commented, “By embedding the knowledge of assay experts into the analysis software, we provide the foundation for smarter research laboratories. We are pleased to be partnering with the industry leader in LC–MS–MS to achieve this goal.”

For more information please visit ref="http://www.absciex.com">www.absciex.com

Related Content:

News